Priovant - finding options to treat autoimmune diseases

Beyond Biotech - the podcast from Labiotech

US-based biotech company Priovant Therapeutics is dedicated to developing novel therapies for autoimmune diseases with high morbidity and few available treatment options.

The company's lead asset, brepocitinib, is a dual selective inhibitor of TYK2 and JAK1. Through dual TYK2/JAK1 inhibition, brepocitinib suppresses key cytokines linked to autoimmunity—including type I IFN, type II IFN, IL6, IL12, and IL23—with a single, targeted therapy.

Brepocitinib has generated positive data in seven phase 2 studies with oral once-daily administration. It is currently being evaluated in a phase 3 program for dermatomyositis and is entering a phase 3 program for non-infectious uveitis.

This week on the podcast we have a conversation with Priovant’s CEO Benjamin Zimmer about dermatomyositis, non-infectious uveitis, current treatments, potential options, and how brepocitinib is making a difference.

00:55-02:34: About Priovant
02:34-06:38: What are dermatomyositis and non-infectious uveitis?
06:38-08:35: What are the current treatments?
08:35-12:32: What is brepocitinib?
12:32-15:36: Are there other treatments in development?
15:36-17:50: What is your relationship with Pfizer?
17:50-20:48: Brepocitinib clinical trials
20:48-24:06: Future plans and timeline
24:06-27:59: Finding patients for clinical trials
27:59-29:19: Future opportunities
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

Hoofdstukken

1. Priovant - finding options to treat autoimmune diseases (00:00:00)

2. About Priovant
 (00:00:55)

3. What are dermatomyositis and non-infectious uveitis?
 (00:02:34)

4. What are the current treatments?
 (00:06:38)

5. What is brepocitinib?
 (00:08:35)

6. Are there other treatments in development?
 (00:12:32)

7. What is your relationship with Pfizer?
 (00:15:36)

8. Brepocitinib clinical trials
 (00:17:50)

9. Future plans and timeline
 (00:20:48)

10. Finding patients for clinical trials
 (00:24:06)

11. Future opportunities (00:27:59)